Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Parmar G, Capra M, Seguro F, Hungria V, Dimopoulos MA, Delimpasi S, Minařík J, Špička I, Pour L, Marques H, Esteves G, Sunami K, Yuda J, Hájek R, Mihályová J, Soufflet C, Yu D, Benlhassan K, Koch V, Comerford E, Cordero P, Suzan F, Quach H

Open source

DOI: 10.1038/s41408-025-01436-0
Published: 2025 Dec 27
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-025-01436-0,
  title = {Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.},
  author = {Parmar G and Capra M and Seguro F and Hungria V and Dimopoulos MA and Delimpasi S and Minařík J and Špička I and Pour L and Marques H and Esteves G and Sunami K and Yuda J and Hájek R and Mihályová J and Soufflet C and Yu D and Benlhassan K and Koch V and Comerford E and Cordero P and Suzan F and Quach H},
  year = {2025},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-025-01436-0},
  url = {https://doi.org/10.1038/s41408-025-01436-0}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
AU  - Parmar G
AU  - Capra M
AU  - Seguro F
AU  - Hungria V
AU  - Dimopoulos MA
AU  - Delimpasi S
AU  - Minařík J
AU  - Špička I
AU  - Pour L
AU  - Marques H
AU  - Esteves G
AU  - Sunami K
AU  - Yuda J
AU  - Hájek R
AU  - Mihályová J
AU  - Soufflet C
AU  - Yu D
AU  - Benlhassan K
AU  - Koch V
AU  - Comerford E
AU  - Cordero P
AU  - Suzan F
AU  - Quach H
PY  - 2025
JO  - Blood cancer journal
DO  - 10.1038/s41408-025-01436-0
UR  - https://doi.org/10.1038/s41408-025-01436-0
ER  -

APA

G, P., M, C., F, S., V, H., MA, D., S, D., J, M., I, Š., L, P., H, M., G, E., K, S., J, Y., R, H., J, M., C, S., D, Y., K, B., V, K., E, C., P, C., F, S., & H, Q. (2025). Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.. Blood cancer journal. https://doi.org/10.1038/s41408-025-01436-0

Source records

pubmed · retrieved 2026-09-26T22:48:32.150Z
europe-pmc · retrieved 2026-09-26T22:48:32.161Z
doaj · retrieved 2026-09-26T22:48:32.167Z